Melissa Johnson, MD, on Advanced Nonsquamous NSCLC: Second-Line Risvutatug Rezetecan and Adebrelimab
Melissa Johnson, MD, of Sarah Cannon Research Institute, reviews results from a cohort of the phase I ARTEMIS-101 trial, which she was the discussant of at AACR 2026. The subgroup of cohort 1a included patients with advanced nonsquamous non–small cell lung cancer and no actionable genomic alterations. The combination of the novel antibody-drug conjugate risvutatug rezetecan and the monoclonal antibody adebrelimab showed a “trend towards improved efficacy” vs monotherapy with risvutatug rezetecan in this patient population (Abstract CT038).